Review
Nature Reviews Drug Discovery 1, 939-950 (December 2002) | doi:10.1038/nrd960
Blocking NO synthesis: how, where and why?
Patrick Vallance1 & James Leiper1 About the authors
Abstract
Nitric oxide (NO) is a key physiological mediator, and the association of disordered NO generation with many pathological conditions has led to much interest in pharmacologically modulating NO levels. However, the wide range of processes in which NO has been implicated, and the fact that increases or decreases in NO levels might be therapeutically desirable depending on the condition or even at different stages of the same condition, pose considerable challenges for drug development. Here, we focus on the rationale and potential for approaches that reduce NO synthesis, which have led to the development of several compounds that will shortly be entering clinical trials.
- View At a Glance
Author affiliations
- Centre for Clinical Pharmacology, British Heart Foundation (BHF) Laboratories, Department of Medicine, University College London, 5 University Street, London WC1E 6JJ, UK.
Correspondence to: Patrick Vallance1 Email: patrick.vallance@ucl.ac.uk
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated REFERENCE RESEARCH |
